Global Nonalcoholic Steatohepatitis (NASH) Market, Analysis, Size, Share, Trends, COVID-19 Impact, and Forecast 2023-2030, By Type, By Application, and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East and Africa)
Market intelx offers the report on “Global Nonalcoholic Steatohepatitis (NASH) Market†Analysis and Forecast 2021-2028. The global Nonalcoholic Steatohepatitis (NASH) market was valued at US$ XX Billion in 2022 and is projected to reach US$ XX Billion in 2030, representing an XX% compound annual growth rate (CAGR) during the forecast period (2023-2030).
The report defines, describes, and forecasts the Nonalcoholic Steatohepatitis (NASH) market, by extensive segments and region. It covers a detailed qualitative and quantitative analysis and various important aspects of the market. These include an analysis of the market dynamics, market analysis, premium insights, COVID-19 impact, segment analysis, regional analysis, competitive landscape, and competitive profiles.
The global Nonalcoholic Steatohepatitis (NASH) market report highlights different scenarios of the Nonalcoholic Steatohepatitis (NASH) Market and offers a comprehensive analysis of historical data (2018-2022 and forecast data (2023-2030), providing a detailed study on driver, restrains, opportunities, challenges, and emerging trends. This report gives a holistic view on market potential, market dynamics, growth opportunities, segmental markets, geographic scenario, competitive analysis, and projections with a suitable set of methodologies and assumptions. The report also provides value chain analysis, PESTLE analysis, Impact analysis, and PORTER’s analysis. Premium insights give you access to insights that include: top trends, key investment pockets, top strategies followed by key players, and access to a strategic research advisor.
This report will enable you to make better informed decisions and gain a future-proof advantage over your competitors, decode the future of market, access intelligence on new technologies, macroeconomic shifts & social trends, make informed business decisions in response to changes in market, revise business plans and react to shifting industry developments, understanding of changing market dynamics, and identify lucrative opportunities.
Research Particulars:
Revenue: USD Million
Base Year: 2022
Forecast Years: 2023-2030 (Forecast for further years (up to 2035) shall be provided upon request)
Historical Years: 2018-2021
Regions Covered: North America, Asia Pacific, Europe, Latin America, and Middle East & Africa
Countries Covered: US, Canada, Mexico, China, India, Japan, South Korea, Germany, United Kingdom, France, Spain, Italy, Brazil, Argentina, GCC, South Africa, and Others.
Market Analysis: Value Chain Analysis, Porters Analysis, Pestle Analysis, COVID-19 Impact Analysis, and Impact Analysis.
Research Methodology
This report provides in-depth qualitative and quantitative analyses of the Global Nonalcoholic Steatohepatitis (NASH) Market. Deep analysis and research were done during the report preparation. We have collected key data related to the Global Nonalcoholic Steatohepatitis (NASH) Market using multiple approaches. Various secondary sources were referred to for the identification and collection of information for this study. Secondary sources include annual reports, press releases, and investor presentations of companies, white papers, medical journals, certified publications, articles from recognized authors, gold standard and silver standard websites, directories, and databases. The primary sources were industry experts from the core and related industries. These include service providers, technology developers, standards and certification organizations, and organizations related to all segments of the value chain. Interviews were conducted with various primary respondents, including key industry participants, C-level executives of key market players, subject-matter experts (SMEs), and industry consultants, to obtain and verify critical qualitative and quantitative information.
Market engineering process (which includes calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation) was completed with extensive primary research and secondary research to verify and validate the critical numbers arrived at. In the entire market engineering process, both top-down and bottom-up approaches were extensively utilised along with several data triangulation methods to perform market sizing and market forecasting for the overall market segments and sub segments listed in this report.
Competitive Overview
The section highlights the key competitors in the market, with a focus on presenting an in-depth analysis on business strategies including merger & acquisitions, partnership/ agreement/ joint venture, business expansion, new product launches, and other developments. This chapter also provides an analysis on leading companies and their positioning and share analysis. Company profiles focusses on in-depth analysis into their product portfolio, financial overview, geographic presence, growth strategies, and SWOT Analysis.
Market Segmentation:
Market intelx provides an analysis of the key segment and each sub-segment of the global Nonalcoholic Steatohepatitis (NASH) market, along with forecasts at the global, regional, and country levels from 2023-2030. This report has segmented the market based on:
Nonalcoholic Steatohepatitis (NASH) Market By Type:
Weight Loss Treatment
Insulin-Sensitizing Agents
Lipid-Lowering Drugs
Antioxidants
Other
Nonalcoholic Steatohepatitis (NASH) Market By Application:
Hospitals
Clinics
Research Institute
Other
Companies Profiles in the Report:
Boehringer Ingelheim, Cerenis Therapeutics, Connexios Life Sciences, Genfit, Islet Sciences, Nimbus Therapeutics, Verva Pharmaceuticals, Viking Therapeutics, Astazeneca Plc, Galmed Pharmaceuticals, GENFIT SA, Gilead Science, Novo Nordisk, Immuron, Intercepts Pharmaceuticals, Enzo Biochem, Tobira Therapeutics.
Regional Coverage
The regional analysis includes the in-depth analysis on North America, Asia Pacific, Europe, Latin America and the Middle East and Africa.
• North America
o US
o Canada
o Mexico
• Asia Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia Pacific
• Europe
o Germany
o UK
o France
o Spain
o Italy
o Rest of Europe
• Latin America
o Brazil
o Argentina
o Rest of the Latin America
• Middle East and Africa
o GCC
o South Africa
o Rest of the Middle East and Africa
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Nonalcoholic Steatohepatitis (NASH) Revenue
1.4 Market Analysis by Type
1.4.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size Growth Rate by Type: 2021 VS 2030
1.4.2 Type 1
1.4.3 Type 2
1.4.4 Type 3
1.4.5 Type 4
1.5 Market by Application
1.5.1 Global Nonalcoholic Steatohepatitis (NASH) Market Share by Application: 2022-2030
1.5.2 Application 1
1.5.3 Application 2
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Nonalcoholic Steatohepatitis (NASH) Market
1.8.1 Global Nonalcoholic Steatohepatitis (NASH) Market Status and Outlook (2016-2030)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Nonalcoholic Steatohepatitis (NASH) Production Capacity Market Share by Manufacturers (2016-2021)
2.2 Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Nonalcoholic Steatohepatitis (NASH) Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Nonalcoholic Steatohepatitis (NASH) Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Nonalcoholic Steatohepatitis (NASH) Sales Volume Market Share by Region (2016-2021)
3.2 Global Nonalcoholic Steatohepatitis (NASH) Sales Revenue Market Share by Region (2016-2021)
3.3 North America Nonalcoholic Steatohepatitis (NASH) Sales Volume
3.3.1 North America Nonalcoholic Steatohepatitis (NASH) Sales Volume Growth Rate (2016-2021)
3.3.2 North America Nonalcoholic Steatohepatitis (NASH) Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.4 East Asia Nonalcoholic Steatohepatitis (NASH) Sales Volume
3.4.1 East Asia Nonalcoholic Steatohepatitis (NASH) Sales Volume Growth Rate (2016-2021)
3.4.2 East Asia Nonalcoholic Steatohepatitis (NASH) Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.5 Europe Nonalcoholic Steatohepatitis (NASH) Sales Volume (2016-2021)
3.5.1 Europe Nonalcoholic Steatohepatitis (NASH) Sales Volume Growth Rate (2016-2021)
3.5.2 Europe Nonalcoholic Steatohepatitis (NASH) Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.6 South Asia Nonalcoholic Steatohepatitis (NASH) Sales Volume (2016-2021)
3.6.1 South Asia Nonalcoholic Steatohepatitis (NASH) Sales Volume Growth Rate (2016-2021)
3.6.2 South Asia Nonalcoholic Steatohepatitis (NASH) Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.7 Southeast Asia Nonalcoholic Steatohepatitis (NASH) Sales Volume (2016-2021)
3.7.1 Southeast Asia Nonalcoholic Steatohepatitis (NASH) Sales Volume Growth Rate (2016-2021)
3.7.2 Southeast Asia Nonalcoholic Steatohepatitis (NASH) Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.8 Middle East Nonalcoholic Steatohepatitis (NASH) Sales Volume (2016-2021)
3.8.1 Middle East Nonalcoholic Steatohepatitis (NASH) Sales Volume Growth Rate (2016-2021)
3.8.2 Middle East Nonalcoholic Steatohepatitis (NASH) Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.9 Africa Nonalcoholic Steatohepatitis (NASH) Sales Volume (2016-2021)
3.9.1 Africa Nonalcoholic Steatohepatitis (NASH) Sales Volume Growth Rate (2016-2021)
3.9.2 Africa Nonalcoholic Steatohepatitis (NASH) Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.10 Oceania Nonalcoholic Steatohepatitis (NASH) Sales Volume (2016-2021)
3.10.1 Oceania Nonalcoholic Steatohepatitis (NASH) Sales Volume Growth Rate (2016-2021)
3.10.2 Oceania Nonalcoholic Steatohepatitis (NASH) Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.11 South America Nonalcoholic Steatohepatitis (NASH) Sales Volume (2016-2021)
3.11.1 South America Nonalcoholic Steatohepatitis (NASH) Sales Volume Growth Rate (2016-2021)
3.11.2 South America Nonalcoholic Steatohepatitis (NASH) Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.12 Rest of the World Nonalcoholic Steatohepatitis (NASH) Sales Volume (2016-2021)
3.12.1 Rest of the World Nonalcoholic Steatohepatitis (NASH) Sales Volume Growth Rate (2016-2021)
3.12.2 Rest of the World Nonalcoholic Steatohepatitis (NASH) Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
4 North America
4.1 North America Nonalcoholic Steatohepatitis (NASH) Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Nonalcoholic Steatohepatitis (NASH) Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Nonalcoholic Steatohepatitis (NASH) Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Nonalcoholic Steatohepatitis (NASH) Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Nonalcoholic Steatohepatitis (NASH) Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Nonalcoholic Steatohepatitis (NASH) Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Nonalcoholic Steatohepatitis (NASH) Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Nonalcoholic Steatohepatitis (NASH) Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Nonalcoholic Steatohepatitis (NASH) Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Nonalcoholic Steatohepatitis (NASH) Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Nonalcoholic Steatohepatitis (NASH) Sales Volume Market Share by Type (2016-2021)
14.2 Global Nonalcoholic Steatohepatitis (NASH) Sales Revenue Market Share by Type (2016-2021)
14.3 Global Nonalcoholic Steatohepatitis (NASH) Sales Price by Type (2016-2021)
15 Consumption Analysis by Application
15.1 Global Nonalcoholic Steatohepatitis (NASH) Consumption Volume by Application (2016-2021)
15.2 Global Nonalcoholic Steatohepatitis (NASH) Consumption Value by Application (2016-2021)
16 Company Profiles and Key Figures in Nonalcoholic Steatohepatitis (NASH) Business
16.1 Company 1
16.1.1 Company 1 Company Profile
16.1.2 Company 1 Nonalcoholic Steatohepatitis (NASH) Product Specification
16.1.3 Company 1 Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.2 Company 2
16.2.1 Company 2 Company Profile
16.2.2 Company 2 Nonalcoholic Steatohepatitis (NASH) Product Specification
16.2.3 Company 2 Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.3 Company 3
16.3.1 Company 3 Company Profile
16.3.2 Company 3 Nonalcoholic Steatohepatitis (NASH) Product Specification
16.3.3 Company 3 Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.4 Company 4
16.4.1 Company 4 Company Profile
16.4.2 Company 4 Nonalcoholic Steatohepatitis (NASH) Product Specification
16.4.3 Company 4 Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.5 Company 5
16.5.1 Company 5 Company Profile
16.5.2 Company 5 Nonalcoholic Steatohepatitis (NASH) Product Specification
16.5.3 Company 5 Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.6 Company 6
16.6.1 Company 6 Company Profile
16.6.2 Company 6 Nonalcoholic Steatohepatitis (NASH) Product Specification
16.6.3 Company 6 Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.7 Company 7
16.7.1 Company 7 Company Profile
16.7.2 Company 7 Nonalcoholic Steatohepatitis (NASH) Product Specification
16.7.3 Company 7 Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.8 Company 8
16.8.1 Company 8 Company Profile
16.8.2 Company 8 Nonalcoholic Steatohepatitis (NASH) Product Specification
16.8.3 Company 8 Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.9 Company 9
16.9.1 Company 9 Company Profile
16.9.2 Company 9 Nonalcoholic Steatohepatitis (NASH) Product Specification
16.9.3 Company 9 Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
17 Nonalcoholic Steatohepatitis (NASH) Manufacturing Cost Analysis
17.1 Nonalcoholic Steatohepatitis (NASH) Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Nonalcoholic Steatohepatitis (NASH)
17.4 Nonalcoholic Steatohepatitis (NASH) Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Nonalcoholic Steatohepatitis (NASH) Distributors List
18.3 Nonalcoholic Steatohepatitis (NASH) Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Nonalcoholic Steatohepatitis (NASH) (2022-2030)
20.2 Global Forecasted Revenue of Nonalcoholic Steatohepatitis (NASH) (2022-2030)
20.3 Global Forecasted Price of Nonalcoholic Steatohepatitis (NASH) (2016-2030)
20.4 Global Forecasted Production of Nonalcoholic Steatohepatitis (NASH) by Region (2022-2030)
20.4.1 North America Nonalcoholic Steatohepatitis (NASH) Production, Revenue Forecast (2022-2030)
20.4.2 East Asia Nonalcoholic Steatohepatitis (NASH) Production, Revenue Forecast (2022-2030)
20.4.3 Europe Nonalcoholic Steatohepatitis (NASH) Production, Revenue Forecast (2022-2030)
20.4.4 South Asia Nonalcoholic Steatohepatitis (NASH) Production, Revenue Forecast (2022-2030)
20.4.5 Southeast Asia Nonalcoholic Steatohepatitis (NASH) Production, Revenue Forecast (2022-2030)
20.4.6 Middle East Nonalcoholic Steatohepatitis (NASH) Production, Revenue Forecast (2022-2030)
20.4.7 Africa Nonalcoholic Steatohepatitis (NASH) Production, Revenue Forecast (2022-2030)
20.4.8 Oceania Nonalcoholic Steatohepatitis (NASH) Production, Revenue Forecast (2022-2030)
20.4.9 South America Nonalcoholic Steatohepatitis (NASH) Production, Revenue Forecast (2022-2030)
20.4.10 Rest of the World Nonalcoholic Steatohepatitis (NASH) Production, Revenue Forecast (2022-2030)
20.5 Forecast by Type and by Application (2022-2030)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2022-2030)
20.5.2 Global Forecasted Consumption of Nonalcoholic Steatohepatitis (NASH) by Application (2022-2030)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Nonalcoholic Steatohepatitis (NASH) by Country
21.2 East Asia Market Forecasted Consumption of Nonalcoholic Steatohepatitis (NASH) by Country
21.3 Europe Market Forecasted Consumption of Nonalcoholic Steatohepatitis (NASH) by Countriy
21.4 South Asia Forecasted Consumption of Nonalcoholic Steatohepatitis (NASH) by Country
21.5 Southeast Asia Forecasted Consumption of Nonalcoholic Steatohepatitis (NASH) by Country
21.6 Middle East Forecasted Consumption of Nonalcoholic Steatohepatitis (NASH) by Country
21.7 Africa Forecasted Consumption of Nonalcoholic Steatohepatitis (NASH) by Country
21.8 Oceania Forecasted Consumption of Nonalcoholic Steatohepatitis (NASH) by Country
21.9 South America Forecasted Consumption of Nonalcoholic Steatohepatitis (NASH) by Country
21.10 Rest of the world Forecasted Consumption of Nonalcoholic Steatohepatitis (NASH) by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer